Abrocitinib In The Treatment Of Moderate to Severe Atopic Dermatitis

Abrocitinib In The Treatment Of Moderate to Severe Atopic Dermatitis Overview This study examined the efficacy and safety of abrocitinib, a treatment for moderate-to-severe atopic dermatitis (AD), specifically focusing on patients with allergic comorbidities.   Data from phase 2b and phase 3 trials were analyzed, pooling information from patients who received abrocitinib or

Salbutamol: A Safety Meta-Analysis

Salbutamol: A Safety Meta-Analysis Overview Salbutamol, a widely used bronchospasm reliever, has been insufficiently scrutinized for potential risks. In a meta-analysis of 58 randomized controlled trials with 12,961 participants, the study unearthed a 34% incidence of total adverse events (AEs). Notably, severe AEs stood at 2%, and treatment discontinuation was 3%. Subgroup

Mepolizumab Effectiveness In Asthma, Rhinosinusitis, and Sinus Surgery Patients

Mepolizumab Effectiveness In Asthma, Rhinosinusitis, and Sinus Surgery Patients Overview In this retrospective cohort study utilizing IQVIA PharMetrics Plus claims data, the effectiveness of mepolizumab, a humanized anti-interleukin 5 monoclonal antibody, was explored in a real-world setting for U.S. patients with severe asthma and comorbid chronic rhinosinusitis (CRS) with or without sinus

Control of Allergic Rhinitis and Asthma Test: A COSMIN Analysis

Control of Allergic Rhinitis and Asthma Test: A COSMIN Analysis Overview The Control of Allergic Rhinitis and Asthma Test (CARAT) serves as a patient-reported outcome measurement (PROM) to evaluate the management of asthma and allergic rhinitis (AR) within a 4-week timeframe. This systematic review aimed to assess CARAT's measurement properties. Adhering to

Childhood BMI and Allergies: A Comprehensive Review

Childhood BMI and Allergies: A Comprehensive Review Allergic conditions such as asthma, eczema, allergic rhinitis, and food allergies are prevalent chronic ailments that affect both children and adults. They pose a range of challenges including psychological stress, disrupted sleep, reduced work productivity, and increased healthcare expenses. Researchers have over time pinpointed

Abrocitinib In The Treatment Of Moderate to Severe Atopic Dermatitis